Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.
Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.
复制标题
DOI：
10.1016/j.addr.2016.08.001
复制
发表时间：
2017-04
影响因子：
16.1
通讯作者：
Cai W
中科院分区：
文献类型：
--
作者：
Goel S;England CG;Chen F;Cai W
开发新型的癌症诊断成像探针对于早期发现和治疗癌症至关重要。在过去的二十年里，放射性标记纳米粒子的发展和演变成为个性化癌症纳米医学的新前沿。正电子发射断层扫描（PET）和纳米技术的动态协同作用将PET的灵敏度和定量特性与纳米材料的多功能性和可调性相结合，这有助于克服该领域的某些关键挑战。在这篇综述中，我们讨论了放射医学的最新进展，例如能够定制纳米材料的物理化学性质，以实现最佳的体内药代动力学和活体目标分子成像。重点介绍了在开发简便和强大的放射性标记策略以及这种放射性探针在癌症治疗中的生物医学应用方面的创新。在放射性标记纳米材料的临床转化迫在眉睫的问题也进行了讨论，重点是需要多学科的努力，迅速将这些有前途的药物从实验室转移到床边。
Development of novel imaging probes for cancer diagnosis is critical for early disease detection and management. The past two decades have witnessed a surge in the development and evolution of radiolabeled nanoparticles as a new frontier in personalized cancer nanomedicine. The dynamic synergism of positron emission tomography (PET) and nanotechnology combines the sensitivity and quantitative nature of PET with the multifunctionality and tunability of nanomaterials, which can help overcome certain key challenges in the field. In this review, we discuss the recent advances in radionanomedicine, exemplifying the ability to tailor the physicochemical properties of nanomaterials to achieve optimal in vivo pharmacokinetics and targeted molecular imaging in living subjects. Innovations in development of facile and robust radiolabeling strategies and biomedical applications of such radionanoprobes in cancer theranostics are highlighted. Imminent issues in clinical translation of radiolabeled nanomaterials are also discussed, with emphasis on multidisciplinary efforts needed to quickly move these promising agents from bench to bedside.